Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.
2023年11月2日 - 8:00PM
Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract
research organization (CRO), today announced that it has completed
a multi-year effort to expand its clinical pharmacology solutions
and capacity, which are now fully available for customers. The
expansion includes a 100,000 square feet state-of-the-art facility
in Leeds, U.K. as well as approximately 20,000 square feet of new
or renovated space, adding capacity and capabilities across its
clinical research units (CRUs) in Dallas, Texas; Daytona, Florida;
and Madison, Wisconsin.
“The increasing complexity of clinical pharmacology studies
demands fit-for-purpose infrastructure, experience and expertise to
protect the safety of study participants and the integrity of
critically important data,” said Oren Cohen, M.D., Fortrea’s
president of Clinical Pharmacology and chief medical officer. “Our
integrated platform of services includes best-in-class
infrastructure and experienced professionals who are fully
dedicated to clinical pharmacology, including physicians, nurses,
clinical scientists, CRAs and pharmacokineticists. The investments
we have made target the capabilities and capacity that customers
need to accurately assess early pipeline candidates and speed those
with promise to later-phase development and ultimately to patients
who need them.”
Facility enhancements following the completed expansion include
Fortrea’s new CRU in Leeds as well as purpose-built rooms in
Madison and Daytona designed for flexibility in executing complex
early phase clinical studies. Improvements in recreational, living
and “work-from-home” spaces at Fortrea CRUs have been constructed
to enhance the experience of volunteers participating in research
at the sites.
The expansion of Fortrea’s early clinical development pharmacy
services facilities includes new state-of-the-art cGMP pharmacies
in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP
pharmacies within them. This enables on-site manufacture of sterile
and non-sterile drug product. The design of its GMP-compliant
facilities provides safe handling and delivery of GMP-quality drug
product for the unique demands of clinical pharmacology studies,
focusing on efficiency and flexibility with the level of controls
expected by regulatory authorities and sponsors.
Enhancements in science and technology include the addition of
artificial intelligence-enabled programs that optimize bed space
utilization and clinic scheduling, and the application of failure
modes and effects analysis to de-risk study execution before a
study begins. Following investments in data collection systems, all
clinical pharmacology study data collected within Fortrea’s CRUs
are input directly into a digital bedside data capture system,
which can also be used as an efficient electronic data capture
solution.
“I believe Fortrea’s early clinical development solutions set a
new standard for what the research industry should expect from its
partners,” said Dr. Cohen. “I’m so proud of this team and know they
will also benefit from the changes we have made. Just as they are
inspired by our mission of bringing life-changing treatments to
patients faster, I’m inspired by their dedication each day as we
deliver solutions to our customers.”
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical
development and patient access solutions to the life sciences
industry. We partner with emerging and large biopharmaceutical,
medical device and diagnostic companies to drive healthcare
innovation that accelerates life changing therapies to patients in
need. Fortrea provides phase I-IV clinical trial management,
clinical pharmacology, differentiated technology enabled trial
solutions and post-approval services.
Fortrea’s solutions leverage three decades of experience
spanning more than 20 therapeutic areas, a passion for scientific
rigor, exceptional insights and a strong investigator site network.
Our talented and diverse team of more than 19,000 people working in
more than 90 countries is scaled to deliver focused and agile
solutions to customers globally.
Learn more about how Fortrea is becoming a transformative force
from pipeline to patient at Fortrea.com and follow us on
LinkedIn and X (formerly Twitter) @Fortrea.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements in this press release, particularly those
relating to the anticipated financial and other benefits,
including, but not limited to, whether the investments at clinical
research units in U.S. and U.K. will add capacity, improve
therapeutic capabilities, enhance experience for study volunteers,
speed development to later-phase trials and improve the integrity
of data and whether the addition of artificial intelligence-enabled
programs will optimize bed space utilization and clinic scheduling,
are forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, many of
which are beyond the Company’s control. Actual results could differ
materially from expectations expressed or implied in the
forward-looking statements if one or more of the underlying
assumptions or expectations prove to be inaccurate or are
unrealized. Important factors that could cause actual results to
differ materially from such expectations are and will be detailed
in Fortrea’s registration statement on Form 10 initially filed with
the SEC on May 15, 2023 (as amended and further supplemented),
Fortrea’s quarterly report on Form 10-Q filed with the SEC on
August 14, 2023, and in Fortrea’s other filings with the SEC. These
forward-looking statements are based on management’s current
expectations and are subject to certain risks, uncertainty and
changes in circumstances. Fortrea does not undertake responsibility
for updating these statements, and these statement speak only as of
the date of this press release.
Fortrea Contacts:
Fortrea Media: Sue Zaranek – 919-943-5422,
media@fortrea.comFortrea Media: Kate Dillon – 646-818-9115,
kdillon@prosek.com Fortrea Investors: Hima Inguva –
877-495-0816, hima.inguva@fortrea.com
Fortrea (NASDAQ:FTRE)
過去 株価チャート
から 5 2024 まで 6 2024
Fortrea (NASDAQ:FTRE)
過去 株価チャート
から 6 2023 まで 6 2024